Federal commission, Federal agency

Pharmaceutical major Zydus Cadila said on Monday it has got approval from Mexico's Federal Commission for the Protection against Stary Risk (COFEPRIS) for its one of its lead research candidate Desidustat to be tested in the management of COVID-19.The clinical and regulatory development of Desidustat in COVID-19 is being executed in Mexico by Avant Sante Research Centre, a leading contract research orgsation headquartered in Monterrey."The company will be conducting a phase 2b, multi-centre, open-label, randomised, comparator-controlled study to evaluate the efficacy and safety of Desidustat tablet for the management of Covid-19 patients," said Zydus in a statement.As a part of the study, 100 mg tablets of Desidustat will be administered for a period of 14 days along with recommended standard care during the trial.Patients infected with COVID-19 have been reported to display signs of hypoxia, leading to organ failure and death despite the use of anti-virals, anti-inflammatory drugs or ventilators.Zydus said the attack with the novel coronavirus pneumonia (COVID-19) will cause less and less haemoglobin that can carry oxygen and carbon dioxide. The lung cells have been reported to develop extremely intense poisoning and inflammation due to the inability to exchange carbon dioxide and oxygen frequently, which eventually results in ground-glass-like lung images.Desidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor which is currently undergoing phase three trials, mimics the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilisation of hypoxia-inducible factor, and this can lead to increased red blood cell production and improved oxygen delivery to tissues."At Zydus, we have been stepping up our efforts to fight the COVID-19 pandemic through therapeutic drugs, diagnostics and vaccines," said Chairman Pankaj R Patel. "With Desidustat, we will study a novel approach for the management of COVID-19," he added.At 10:50 am, the company's stock was trading 2.2 per cent higher at Rs 1,357 per unit.( With inputs from ANI )

Home

City

Latest News

Cricket

LT Premium

National

International

Maharashtra

Opinions

Chhatrapati Sambhajinagar

Nagpur

Entertainment

Photos

Business

Technology

Sports

Lifestyle

Social Viral

Lokmat Games

Health

Lok Sabha Election 2024

Heatwave In India

Mumbai Water Cut

Maharashtra Lok Sabha Election

IPL 2024

Salman Khan

Federal CommissionFOLLOW

Federal commission, Latest News

Health :62 salmonella infections linked to Belgian chocolate factory

Brussels, May 14 An investigation has concluded that 62 people were infected with salmonella after consuming Kinder chocolate ... ...

Business :Zydus gets Mexican regulator nod to conduct clinical trials with Pegylated Interferon alpha-2b to treat COVID-19

Pharmaceutical major Zydus said on Friday it has got approval from Mexico's Federal Commission for the Protection against Sanitary Risk (COFEPRIS) to conduct clinical trials with its biological therapy 'Pegylated Interferon alpha-2b' for the treatmen ...

Business :Zydus gets Mexican regulator nod for Desidustat in test management of COVID-19

Pharmaceutical major Zydus Cadila said on Monday it has got approval from Mexico's Federal Commission for the Protection against Sanitary Risk (COFEPRIS) for its one of its lead research candidate Desidustat to be tested in the management of COVID-19 ...